• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Long-Term Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for CD: Results From the VIVID-2 Open-Label Extension Study.维多珠单抗连续治疗104周对克罗恩病的长期疗效和安全性：VIVID-2开放标签扩展研究结果
Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):17-18.
2
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.溃疡性结肠炎连续治疗152周后mirikizumab的三年疗效和安全性：LUCENT-3开放标签扩展研究结果
Inflamm Bowel Dis. 2024 Oct 25. doi: 10.1093/ibd/izae253.
3
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.mirikizumab改善中度至重度活动性克罗恩病患者的生活质量和工作效率：3期VIVID-1研究结果
Am J Gastroenterol. 2025 Mar 13;120(8):1809-19. doi: 10.14309/ajg.0000000000003410.
4
Mirikizumab Pharmacokinetics and Exposure-Response in Patients With Moderately-To-Severely Active Crohn's Disease: Results From Two Randomized Studies.中度至重度活动性克罗恩病患者中mirikizumab的药代动力学和暴露-反应关系：两项随机研究的结果
Clin Transl Sci. 2025 Aug;18(8):e70320. doi: 10.1111/cts.70320.
5
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.mirikizumab治疗对中度至重度活动性克罗恩病患者疲劳的影响：3期VIVID-1研究结果
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjaf100.
6
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
7
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.瑞莎珠单抗治疗中度至重度斑块状银屑病的长期安全性和有效性：LIMMitless 3期最终开放标签扩展试验结果
Am J Clin Dermatol. 2025 Jul 29. doi: 10.1007/s40257-025-00964-6.
8
Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy Participants.健康受试者皮下注射mirikizumab后自动注射器与预填充注射器之间的药代动力学桥接
Adv Ther. 2025 Sep 3. doi: 10.1007/s12325-025-03335-z.
9
Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials.古塞奇尤单抗治疗银屑病的疗效与安全性：一项随机对照试验的系统评价和荟萃分析
Inflammopharmacology. 2025 Mar;33(3):1033-1042. doi: 10.1007/s10787-025-01658-5. Epub 2025 Feb 15.
10
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.比美吉珠单抗完全清除皮肤和指甲银屑病：III期/IIIb期研究中的疗效对比
Am J Clin Dermatol. 2025 Aug 31. doi: 10.1007/s40257-025-00968-2.

本文引用的文献

1
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.mirikizumab治疗中度至重度活动性克罗恩病患者的疗效和安全性：一项3期、多中心、随机、双盲、安慰剂对照和活性对照的持续治疗研究。
Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21.

Long-Term Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for CD: Results From the VIVID-2 Open-Label Extension Study.

出版信息

Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):17-18.

PMID:40893182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397776/
Abstract
摘要